Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease?

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Should the apolipoprotein E (ApoE) genotype be a covariate for clinical trials in Alzheimer disease (AD)? ApoE is a transport protein for lipids, amyloid-beta proteins, and the different phenotypes differentially affect amyloid-beta deposition, neurofibrillary tangle formation, and microglial activation. The ApoE genotype has not affected efficacy in short symptomatic AD trials. ApoE4 has been associated with greater efficacy in at least two mild cognitive impairment studies. Vasogenic edema was more frequent in ApoE4 AD patients treated with a monoclonal antibody to amyloid beta. Since there is evidence that the ApoE genotype may differentially affect disease mechanisms, efficacy, and adverse effects in both AD and mild cognitive impairment trials, the ApoE genotype should be included as a covariate in future studies.

Original languageEnglish
Article number15
JournalAlzheimer's Research and Therapy
Volume2
Issue number3
DOIs
StatePublished - 2010

Fingerprint

Apolipoproteins E
Alzheimer Disease
Genotype
Clinical Trials
Apolipoprotein E4
Amyloid
Neurofibrillary Tangles
Amyloid beta-Peptides
Edema
Carrier Proteins
Monoclonal Antibodies
Phenotype
Lipids
Cognitive Dysfunction

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Cognitive Neuroscience

Cite this

Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease? / Farlow, Martin.

In: Alzheimer's Research and Therapy, Vol. 2, No. 3, 15, 2010.

Research output: Contribution to journalArticle

@article{edff994f4dff4bef86ebebce5d1b2742,
title = "Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease?",
abstract = "Should the apolipoprotein E (ApoE) genotype be a covariate for clinical trials in Alzheimer disease (AD)? ApoE is a transport protein for lipids, amyloid-beta proteins, and the different phenotypes differentially affect amyloid-beta deposition, neurofibrillary tangle formation, and microglial activation. The ApoE genotype has not affected efficacy in short symptomatic AD trials. ApoE4 has been associated with greater efficacy in at least two mild cognitive impairment studies. Vasogenic edema was more frequent in ApoE4 AD patients treated with a monoclonal antibody to amyloid beta. Since there is evidence that the ApoE genotype may differentially affect disease mechanisms, efficacy, and adverse effects in both AD and mild cognitive impairment trials, the ApoE genotype should be included as a covariate in future studies.",
author = "Martin Farlow",
year = "2010",
doi = "10.1186/alzrt39",
language = "English",
volume = "2",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "3",

}

TY - JOUR

T1 - Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease?

AU - Farlow, Martin

PY - 2010

Y1 - 2010

N2 - Should the apolipoprotein E (ApoE) genotype be a covariate for clinical trials in Alzheimer disease (AD)? ApoE is a transport protein for lipids, amyloid-beta proteins, and the different phenotypes differentially affect amyloid-beta deposition, neurofibrillary tangle formation, and microglial activation. The ApoE genotype has not affected efficacy in short symptomatic AD trials. ApoE4 has been associated with greater efficacy in at least two mild cognitive impairment studies. Vasogenic edema was more frequent in ApoE4 AD patients treated with a monoclonal antibody to amyloid beta. Since there is evidence that the ApoE genotype may differentially affect disease mechanisms, efficacy, and adverse effects in both AD and mild cognitive impairment trials, the ApoE genotype should be included as a covariate in future studies.

AB - Should the apolipoprotein E (ApoE) genotype be a covariate for clinical trials in Alzheimer disease (AD)? ApoE is a transport protein for lipids, amyloid-beta proteins, and the different phenotypes differentially affect amyloid-beta deposition, neurofibrillary tangle formation, and microglial activation. The ApoE genotype has not affected efficacy in short symptomatic AD trials. ApoE4 has been associated with greater efficacy in at least two mild cognitive impairment studies. Vasogenic edema was more frequent in ApoE4 AD patients treated with a monoclonal antibody to amyloid beta. Since there is evidence that the ApoE genotype may differentially affect disease mechanisms, efficacy, and adverse effects in both AD and mild cognitive impairment trials, the ApoE genotype should be included as a covariate in future studies.

UR - http://www.scopus.com/inward/record.url?scp=81755170928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81755170928&partnerID=8YFLogxK

U2 - 10.1186/alzrt39

DO - 10.1186/alzrt39

M3 - Article

C2 - 20537201

AN - SCOPUS:81755170928

VL - 2

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

SN - 1758-9193

IS - 3

M1 - 15

ER -